-transparent.png){kind=logo}
Twenty-nine evaluable patients with endometrial cancer were treated with amonafide 300 mg/m2 for 5 consecutive days every 3 weeks. Two partial responses (8%) were seen. Hematologic toxicity was severe or life-threatening in 13 patients occurring as follows: leukopenia in 13 patients (45%); thrombocytopenia in 10 patients (34%); granulocytopenia in 13 patients (45%); and anemia in four patients (14%). In view of the low response rate and high toxicity, this dose schedule of amonafide does not warrant further investigation in endometrial cancer.
Related Publications
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
February 1994,
American journal of clinical oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
February 1993,
Anti-cancer drugs,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
January 1993,
Investigational new drugs,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
August 1992,
Gynecologic oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
June 2011,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
October 2014,
Gynecologic oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
February 2002,
Gynecologic oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
June 2003,
Gynecologic oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
May 2007,
Gynecologic oncology,
R Asbury, and
J A Blessing, and
G C Reid, and
W P McGuire
December 2002,
Gynecologic oncology,
